文献速递神经肌肉病神经免疫

儿童神经病学:ACOX1功能获得性变异相关的神经退行性脑脊髓病对免疫治疗部分有效

Child Neurology: Neurodegenerative Encephalomyelopathy Associated With ACOX1 Gain-of-Function Variation Partially Responsive to Immunotherapy.
PubMed 文献 · Neurology · 2022-06-17

报告一例19岁女性,有5年纵贯性后部为主脊髓病、双侧角膜瘢痕和白质病变病史,后出现首次癫痫发作、进行性感音神经性听力损失、鱼鳞病样皮疹和马尾综合征。全外显子组测序4年前无诊断,再次分析发现ACOX1杂合变异(c.710A>G,p.Asn237Ser),考虑致病。高剂量类固醇无效,IVIg和低剂量吗替麦考酚酯治疗6个月后稳定并改善至基线,免疫治疗下临床稳定超过1年。

要点

  • ACOX1功能获得性变异导致活性氧过量产生,引起进行性神经退行性变伴离散复发。
  • 对既往无诊断的基因组/外显子组测序数据进行再分析可发现致病性变异。
  • 免疫治疗(IVIg和低剂量吗替麦考酚酯)可能改变这种通常普遍致命疾病的病程。

核心结论

  • ACOX1功能获得性变异相关的神经退行性脑脊髓病对免疫治疗部分有效,患者临床稳定超过1年,提示可能改变疾病进程。

研究设计与样本

  • 病例报告:一例19岁女性,有5年纵贯性后部为主脊髓病、双侧角膜瘢痕和白质病变病史。

主要发现

  • 患者表现为首次癫痫发作、进行性感音神经性听力损失、鱼鳞病样皮疹和马尾综合征,广泛检查无阳性发现。
  • 高剂量类固醇治疗无反应,IVIg和低剂量吗替麦考酚酯治疗6个月后稳定并改善至基线。
  • 全外显子组测序4年前无诊断,再次分析发现ACOX1杂合变异(NM_004035.6: c.710A>G, p.Asn237Ser),现认为致病。
  • 免疫治疗下临床稳定超过1年。

临床怎么用

  • 作者认为,对既往无诊断的基因组/外显子组测序数据进行再分析很重要。
  • 作者指出,患者免疫治疗下临床稳定超过1年,提示可能改变这种通常普遍致命疾病的病程。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Acyl-CoA oxidase 1 (ACOX1) is a peroxisomal enzyme involved in beta-oxidation of very-long-chain fatty acids. Although loss of function of ACOX1 had been previously described, gain-of-function variation of ACOX1 gene has been only recently identified, with a paucity of known cases. Gain-of-function variation results in overproduction of reactive oxygen species, resulting in progressive neurodegeneration with discrete relapses. We report the case of a 19-year-old woman with a 5-year history of longitudinally extensive posterior predominant myelopathy, bilateral corneal scars, and white matter lesions who presented with first-time seizure, progressive sensorineural hearing loss, ichthyosiform rash, and cauda equina syndrome. Extensive workup was unrevealing. The patient showed no response to high-dose steroids but stabilization and improvement with return to baseline over 6 months with IVIg and low-dose mycophenolate mofetil. Whole-exome sequencing performed 4 years before was nondiagnostic, but subsequent reanalysis revealed a heterozygous variation in the ACOX1 gene (NM_004035.6: c.710A>G, p.Asn237Ser), now considered to be pathogenic. This case reports a rare condition and highlights the importance of reanalysis of previously nondiagnostic genome/exome sequencing data. Furthermore, the patient's clinical stability for over 1 year on immunotherapy raises the possibility of disease modification in an otherwise universally fatal condition.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Jafarpour S, Khoshnood M, Santoro JD, et al. Child Neurology: Neurodegenerative Encephalomyelopathy Associated With ACOX1 Gain-of-Function Variation Partially Responsive to Immunotherapy. Neurology. 2022. PMID: 35715200. doi:10.1212/WNL.0000000000200935

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。